Artemisinin inhibits angiogenesis by down-regulating HIF-1α and VEGF expression in mouse embryonic stem cells. Artemisinin crosses the blood-brain barrier and is an inhibitor of human NOS2 (iNOS).
Jurg Utzinger; Shu-Hua Xiao; Marcel Tanner; Jennifer Keiser. Artemisinins for schistosomiasis and beyond. Current Opinion in Investigational Drugs. 2007, 8, (2), 105-116.
Rita Piedade; José Pedro Gil. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opinion on Drug Metabolism and Toxicology. 2011, 7, (10), 1185-1200.